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Department of Respiratory Medicine, Nutrition and Toxicology Research Institute, University of Maastricht,
P.O. Box 5800, 6202 AZ Maastricht, The NetherlandsChronic obstructive pulmonary disease
(COPD) is a chronic lung disease characterized by
at least partially irreversible airway obstruction
and an abnormal chronic inflammatory response of
the airways. Dominant symptoms are dyspnea and
impaired exercise capacity. These symptoms lead to
progressive disability and poor health status but
correlate poorly with severity of local impairment
in the lungs. Surprisingly, even in the most recent
international guidelines for diagnosis of COPD,
staging is still based on severity of airways obstruc-
tion only. There is increasing evidence in the
literature that COPD should not be considered
a localized pulmonary disorder but a systemic
disease that involves pathology in several extrap-
ulmonary tissues. Well-characterized systemic
features include chronic low-grade systemic in-
flammation and altered regulation of protein me-
tabolism, which result initially in muscle atrophy
only (commonly referred to as sarcopenia) but in
later stages also result in cachexia [1,2].
Muscle atrophy is associated with increased
mortality risk independent of disease staging
based on severity of airflow obstruction [3]. Be-
sides muscle atrophy, it is well established that
intrinsic abnormalities in muscle structure and
metabolism are present in moderate to severe
cases of COPD and that both processes contribute
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In turn, skeletal muscle dysfunction adversely
affects clinical outcome in COPD, because it is
an independent determinant of exercise limitation
[4,5]. In this article we present a state-of-the-art
update on skeletal muscle dysfunction and sys-
temic inflammation in patients who have COPD
and discuss the therapeutic potential of novel
insights from experimental research in the regula-
tion of muscle plasticity.
Characterization and causes of skeletal muscle
dysfunction in chronic obstructive pulmonary
disease
Skeletal muscle dysfunction in COPD is char-
acterized by a reduction in strength and endur-
ance of the muscle. Skeletal muscle strength is
largely determined by muscle mass. Data clearly
indicate that atrophy of skeletal muscles is appar-
ent in COPD and that the disease selectively
affects the predominant glycolytic type IIA/IIX
fibers [6,7]. Loss of muscle mass is a complex pro-
cess that involves changes in the control of sub-
strate and protein metabolism and changes in
muscle cell turnover. Impaired protein metabo-
lism may result in muscle atrophy when protein
degradation exceeds protein synthesis. To date,
a limited number of studies have addressed pro-
tein metabolism in patients who have COPD. Us-
ing stable isotope techniques, two studies haveghts reserved.
chestmed.theclinics.com
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who have COPD. Morrison and colleagues [8]
demonstrated a decreased muscle protein synthe-
sis in underweight patients with emphysema.
More recently, Rutten and colleagues [9] showed
an elevated myofibrillar protein breakdown in
cachectic patients who had COPD, whereas no
difference was seen between noncachectic patients
who had COPD and healthy controls. At the cel-
lular level, increased apoptosis of muscle cells has
been demonstrated in skeletal muscle of severely
underweight patients who have COPD [10], al-
though this observation was not confirmed in
weight-stable patients who have COPD and are
suffering from muscle wasting [11]. This finding
could implicate different mechanisms in loss of
muscle mass in the absence or presence of weight
loss (ie, sarcopenia versus cachexia).
Reduced muscle endurance, on the other hand,
is not associated with muscle wasting but may be
secondary to either intrinsic muscle alterations
(mitochondrial abnormalities and loss of contrac-
tile proteins) or alterations in the external milieu in
which the muscle works (hypoxia, hypercapnia,
and acidosis) that result from the abnormalities of
pulmonary gas exchange that exist in COPD.
Gosker and colleagues [12] showed that in COPD
there is a shift in muscle fiber type from type I
(slow twitch, oxidative fibers) to type II (fast twitch
glycolytic) fibers. Type I fibers are resistant to
fatigue, whereas type II fibers are more fatigable.
A decrease in the percentage of type I fibers in the
vastus lateralis of patients who have COPD com-
pared with age-matched controls was reported
together with a corresponding increase in type IIx
fibers [12].Researchhas shown consistently that pe-
ripheral muscles of patients who have COPD are
characterized by reduced activities of enzymes in-
volved in muscle oxidative metabolism as citrate
synthase and b-hydroxyacylCoA dehydrogenase
[12,13]. Conversely, activities of glycolytic enzymes
were found to be increased in lower limb muscle
of patients who have COPD by some studies [13].
Because these enzyme activities depend largely on
fiber type [14], it is likely that this shift in activities
is related to the shift in fiber distributionmentioned
previously. Whether enzyme activities adapt to the
fiber type or the other way around remains unclear.
Further indication of an impaired energy
metabolism in patients who have COPD is derived
from studies that measured substrate and cofactor
concentrations in peripheral skeletal muscle of
patients who have COPD. Most striking was
the observation of reduced concentrations ofhigh-energy phosphates at rest, as indicated by
elevated levels of inosine monophosphate [15].
Muscle glycogen content in COPD also tends to
be lower, whereas lactate concentrations are
higher than in healthy persons [16,17]. These
data indicate that anaerobic energy metabolism
is enhanced in COPD. Because this process yields
far less ATP than complete oxidative degradation
of glucose, a reduced energy state in COPD could
not only limit exercise endurance but also contrib-
ute to a decreased work efficiency that has been re-
ported during cycle exercise [18] and elevated
energy expenditure in some patients [19]. We hy-
pothesized that uncoupling protein 3 (UCP-3),
which uncouples oxidative phosphorylation from
ATP production, is implicated in the elevated en-
ergy expenditure in COPD. Gosker and colleagues
[20], however, demonstrated that instead of the
expected increase in skeletal muscle UCP-3 con-
tent, UCP-3 protein levels were decreased in skel-
etal muscle of patients who have COPD. UCP-3
also has been postulated as an important factor
in the defense against lipid-induced oxidative
muscle damage [21]. Markers of oxidative stress
are elevated in skeletal muscle of patients who
have COPD at rest and during exercise [22]. Con-
sequently, impaired skeletal muscle antioxidant
defenses also have been reported [23].
Characterization and sources of systemic
inflammation in chronic obstructive pulmonary
disease
By definition, COPD is a disorder character-
ized by reduced maximum expiratory flow and
slow forced emptying of the lungs caused by
varying combinations of diseases of the airways
and emphysema. Progression of the disease is
associated with an intense chronic inflammation
of the lungs, and the critical role of this local
inflammatory process in the pathogenesis and
progression of COPD is generally recognized
and accepted. In addition to airway inflammation,
there is increasing evidence of low-grade systemic
inflammation in COPD. In contrast to extensive
knowledge of the inflammatory process in the
airways of patients who have COPD, surprisingly
less is known about systemic inflammation in this
disorder. Although the exact relationship between
inflammation in the lung and in the systemic
compartment remains to be established, an inverse
relationship has been shown between the presence
of systemic inflammation and the mean forced
expiratory volume in 1 second in patients, which
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tion in disease progression [24].
According to a recent meta-analysis, several
clinical studies have reported persistent systemic
inflammation in COPD, as evidenced by elevated
levels of the proinflammatory cytokines tumor
necrosis factor-alpha (TNF-a), interleukin-6
(IL-6), IL-8, and the soluble TNF-a receptors
(sTNFR-55 and sTNFR-75) [25,26]. Proinflam-
matory cytokines such as IL-6 and TNF-a have
been shown to induce the formation of acute
phase reactants. One of the major acute phase
proteins, C-reactive protein, is increased in the cir-
culation of patients who have COPD compared to
healthy controls [27]. High C-reactive protein
levels in the circulation of patients who have
COPD have been associated with reduced quadri-
ceps strength, lower maximal and submaximal ex-
ercise capacity, and increased mortality [28,29].
The origin of the systemic inflammation in
patients who have COPD remains poorly under-
stood; several (independent) pathways may be
involved. Although a relationship between lung
and systemic inflammation has been suggested,
evidence from available cross-sectional studies in-
dicates no clear correlation between the presence of
inflammation in the pulmonary and systemic com-
partments [30]. This finding suggests that the sys-
temic inflammatory response is not caused by an
overflow of inflammatory mediators from the pul-
monary compartment but is regulated differently.
Potential nonpulmonary sources of systemic in-
flammatory mediators include inflammatory cells
in the circulation, because several studies have
shown increased levels of various circulating in-
flammatory cells, including neutrophils and lym-
phocytes, in peripheral blood of patients who
have COPD. The activation of peripheral blood
lymphocytes, which results in potentiation of cyto-
toxic andmigratory responses, also has been shown
[31].
A second pathway involved in the process of
systemic inflammation could be hypoxia, which is
often present in patients who have severe COPD.
Several in vitro studies have shown that hypoxia
results in enhanced cytokine production by macro-
phages, which could contribute to activation of the
TNF-a system in COPD. Takabatake and col-
leagues [32] showed a significant inverse relation-
ship between arterial oxygen pressure and
circulating levels of TNF-a and soluble TNF-R in
patients who have COPD. Alternatively, increased
levels of inflammatory mediators in the blood of
patients who have COPD may originate frommuscle cells or yet-unexplored extrapulmonary
cells, including endothelium and fat tissue. Skeletal
muscle itself is capable of constitutive and inducible
production of proinflammatory cytokines, such as
TNF-a and IL-6 [33,34]. Data on the contribution
of extrapulmonary cells to the ongoing inflamma-
tory process in COPD is, to date, lacking.
Several studies have shown that systemic in-
flammatory cytokines, such asTNF-a and IL-6, are
proximal markers of cachexia and selectively target
myosin protein content in skeletal muscle. High
levels of IL-6 have been associated with reduced
quadriceps strength and diminished exercise capac-
ity [29], and TNF-a has been shown to be inversely
related to muscle mass [35]. These cytokines may
cause skeletal muscle weakness without causing
muscle wasting by directly compromising contrac-
tile properties of the skeletal musculature. De Oca
and colleagues [36] showed that TNF-a protein
levels in skeletal muscle of patients who have
COPD were markedly higher compared to healthy
control subjects. A study by Agusti and colleagues
[37] also suggested that patients who have severe
COPD and are suffering from weight loss are char-
acterized by increased activation of the transcrip-
tion factor nuclear factor kappa B (NF-kB),
a major signaling pathway that conveys inflamma-
tory signals, in skeletal muscle.
These studies indicated that the systemic in-
flammatory process in COPD also involves the
skeletal musculature itself. Although recent stud-
ies showed a clear association between C-reactive
protein and impaired muscle function and exercise
capacity, even after adjustment for mean forced
expiratory volume in 1 second, it is unclear if this
association is linked to effects on muscle mass or
caused by direct effects on muscle contractility
[38]. In summary, a large body of evidence sug-
gests that systemic inflammation is present in pa-
tients who have COPD, and several lines of
evidence indicate a significant role of inflamma-
tory mediators in disturbed regulation of muscle
mass and muscle functional capacity. Because
most data in this context originated from studies
with a cross-sectional design, longitudinal studies
are needed to unravel the exact role of systemic
inflammation in the progression of COPD and
the impairment of skeletal muscle function.
Novel insights in the regulation of muscle mass
during muscle wasting
Abundant evidence from in vitro research and
experimental models indicates that inflammatory
540 REMELS et alstimuli trigger weight loss and muscle atrophy
[35,39–41].Muscle loss has been documented in an-
imals treated with exogenous TNF-a, in animals
that express a TNF transgene, and in diseases that
elevate endogenous TNF-a (ie, experimental sepsis
or tumor implantation) [41]. Several studies also
point to the importance of IL-6 in the regulation
of muscle wasting [35,42]. Little information is
available, however, on how elevated and circula-
tory levels of inflammatory mediators, such as
TNF-a and IL-6, convey signaling cues that cause
skeletal muscle to atrophy. Upon binding to their
cognate receptors at the myofiber surface, proin-
flammatory cytokines, such as TNF-a and IL-1b,
cause activation of the transcription factor
NF-kB. Under basal conditions, NF-kB is present
within the cytoplasm in an inactive state, bound
to its inhibitory protein IkBa. Upon stimulation
with an inflammatory stimulus (eg, TNF-a) an in-
tracellular signaling cascade is initiated, which re-
sults in the phosphorylation of IkBa by IkB
kinase and subsequent degradation of IkBa. Once
liberated from its inhibitory protein, NF-kB trans-
locates into the nucleus, where it regulates tran-
scription of various inflammatory genes [43].
Although the intracellular signaling initiated by
inflammatory stimuli is certainly not limited to
NF-kB activation in skeletal muscle, recent work
suggests that this pathway is involved in muscle
atrophy signaling.
The exact intracellular mechanisms responsible
for inflammation-induced wasting of skeletal
muscle remain to be elucidated. At the protein
level, an imbalance between protein synthesis and
protein degradation may favor muscle catabolism.
At the cellular level, a disturbed balance between
the loss and gain of nuclei in muscle fibers through
apoptosis and myonuclear accretion, respectively,
may contribute to loss of skeletal muscle mass.
These processes are discussed in further detail
later in this article. Importantly, these processes
are not mutually exclusive but are likely to occur
in parallel during muscle wasting, as has been
shown for their involvement in muscle plasticity in
response to physiologic stimuli.
Effects of inflammation on regulation of muscle
protein turnover
Protein degradation
Work using cultured murine myotubes (eg, the
in vitro equivalents of muscle fibers) demon-
strated that TNF-a directly stimulates a time- andconcentration-dependent decrement in total mus-
cle protein content and loss of muscle-specific
proteins, including fast-type myosin heavy chain
(MyHC). MyHC losses were not accompanied by
a change in synthesis rate, which suggests that
TNF-a stimulated degradation of myofibrillar
proteins rather than inhibited their synthesis
[41,44]. Research also has demonstrated that infu-
sion with TNF-a increased muscle proteolysis in
rats [45]. Several proteolytic systems could con-
tribute to enhanced protein degradation in
chronic inflammatory disorders, including the
lysosomal pathway, the Ca2þ-dependent pathway,
caspases, and the ATP-dependent ubiquitin pro-
teasome pathway (UPP). Recent in vitro and ani-
mal model–derived evidence postulates the UPP
as the predominant pathway involved in skeletal
muscle atrophy. In this pathway, proteins to be
degraded are tagged by at least four moieties of
the polypeptide ubiquitin (Ub), which are cova-
lently bound at the lysine 48 residue. This process,
named K48-Ub conjugation, requires the sequen-
tial activity of a series of specific enzymes: E1,
or Ub-activation enzyme; E2, or Ub-conjugating
enzyme; and E3, or Ub-ligase. K48-polyubiquiti-
nated proteins are recognized and degraded by
the 26S-proteasome complex into short peptides
that are further rapidly degraded to free amino
acids in the cytosol [46].
Elevated Ub gene expression and Ub conjuga-
tion were reported in skeletal muscle after the
administration of TNF-a in vitro [47]. MyHC de-
pletion in response to TNF-a also occurred via an
upregulation of certain components of the Ub-
proteasome pathway [48]. Several in vivo models
confirm the involvement of TNF-a and the UPP
in wasting of skeletal muscle mass. Increased ex-
pression of muscular Ub and Ub conjugation
were observed in rats after injection of TNF-a
[49]. Two muscle-specific Ub (E3) ligases, atro-
gin-1/MAFbx and MuRF1, also are rate limiting
for muscle protein loss in various catabolic condi-
tions. Expression of these two Ub ligases is upre-
gulated in the muscle of various animal models of
inflammation-associated muscle atrophy, includ-
ing cancer, diabetes, and sepsis, whereas the mus-
cle mass of MAFbx-/- and MuRF1-/- gene
knockout animals is spared in several of these
atrophy models [50–52].
Muscle proteins targeted for degradation by
the UPP in response to inflammatory cytokines
include MyHC and MyoD [53,54]. MyHC is
a myofibrillar protein involved in muscle contrac-
tion, whereas MyoD is a muscle regulatory factor
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muscle growth implicating a mechanism by which
the UPP contributes to muscle atrophy, not only
through degradation of specific muscle proteins
but also via the selective degradation of regulatory
proteins. Several studies have postulated an im-
portant role for NF-kB in this regulation of pro-
tein degradation through the UPP during muscle
atrophy. For instance, loss of MyHC protein in
response to TNF-a corresponded with NF-kB ac-
tivation in cultured myotubes, and inhibition of
NF-kB activity blocked cytokine-mediated de-
creases in muscle-specific proteins [48]. TNF-a in-
creases Ub-conjugating activity in skeletal muscle
cells in vitro in an NF-kB–dependent manner [47].
It was recently established that through muscle-
specific transgenic expression of activated IkB
kinase 2, constitutive activation of NF-kB in skel-
etal muscle was sufficient to induce profound mus-
cle atrophy. Muscle loss in this model was caused
by accelerated protein breakdown through Ub-de-
pendent proteolysis, because expression of the E3
ligase MuRF1, a mediator of muscle atrophy, was
increased and muscle atrophy was ameliorated in
MuRF1-deficient mice [55]. Conversely, skeletal
muscle-specific inhibition of NF-kB activation
preserved muscle tissue in various experimental
models of muscle atrophy [56], which indicated
that muscular NF-kB activation may be required
for the loss of muscle mass in certain (pathologic)
conditions.
Protein synthesis
In addition to increased proteolysis, systemic
inflammation is also associated with decreased
protein synthesis. Protein synthesis is impaired in
muscles of animals subjected to experimental
sepsis [57], and this response seems to involve sys-
temic inflammation, because TNF-a and IL-1b
antagonists have been reported to improve muscle
protein balance in septic rats by preventing de-
creased synthesis rates [58,59]. Conversely, admin-
istration of TNF-a or IL-1b reduced synthesis of
the major muscle proteins in rats [59,60]. Muscle
protein synthesis is under positive control of insu-
lin-like growth factor-1 (IGF-1) signaling. De-
creased circulating IGF-1 levels have been
reported in response to sepsis and IGF-1 resis-
tance of skeletal muscle exposed to inflammatory
cytokines [61]. Skeletal muscle production of
IGF-1, which stimulates protein synthesis and
suppresses degradation in an autocrine fashion,
is reduced by inflammatory mediators [61].Binding of IGF-1 to its receptor initiates a signal
transduction cascade that promotes mRNA trans-
lation and consequently increases protein synthe-
sis [62]. Incubation of skeletal muscle cells with
inflammatory cytokines, including TNF-a and
IL-1b, induces IGF-1 resistance, which is charac-
terized by decreased protein synthesis as a result
of impaired signaling proximal to receptor activa-
tion [63]. The exact molecular mechanism of
inflammation-induced IGF-1 resistance in skeletal
muscle remains to be elucidated but may involve
ceramide as an intermediate, because inhibition
of de novo synthesis of this second messenger pre-
vented impaired IGF-1–induced protein synthesis
by TNF-a or IL-1b [64].
Effects of inflammation on regulation
of myonuclear turnover
Because of its multinucleated nature, the cyto-
plasm (sarcoplasm) of a myofiber is shared by
multiple nuclei, each ofwhich is thought to regulate
protein expression for a defined volume of the
sarcoplasm (eg, the myonuclear domain). Experi-
mental evidence indicates that the dimensions of
the myonuclear domain are relatively constant,
implying flexibility of the myonuclear number to
accommodate muscle plasticity, which is accom-
plished by the addition (myonuclear accretion) or
loss (by apoptosis) of myonuclei during muscle
(fiber) growth and atrophy, respectively [65]. In ad-
dition to an inequity in muscle protein synthesis
and degradation, an imbalanced myonuclear turn-
over may contribute to muscle atrophy in patients
with disorders associated with chronic inflamma-
tion. The effects of inflammatory mediators on cel-
lular mechanisms that regulate apoptosis and
myonuclear accretion are described herein.
Apoptosis
Apoptosis, or programmed cell death, is an
important process in multicellular organisms dur-
ing development but also in postnatal tissue
homeostasis. Apoptosis can be initiated by ligand
binding to so-called ‘‘death receptors’’ (which
include Fas and members of the TNF receptor
family) or by the release of apoptosis-inducing
factors from mitochondria [66]. Subsequently,
protein-cleaving enzymes (caspases) and endonu-
cleases are activated, which results in the
degradation of regulatory proteins and DNA
fragmentation, respectively. In mononuclear cells,
this process ultimately culminates in the
542 REMELS et alformation of apoptotic bodies that are cleared by
macrophages. Because of the multinucleated na-
ture of myofibers, however, the elimination of
one myonucleus by apoptosis is not necessarily
followed by the destruction of the entire myofiber,
and this process is referred to as apoptotic nuclear
death. As a consequence, the mechanisms in-
volved in apoptosis signaling in skeletal muscle
are likely distinct from mononucleated cells.
DNAfragmentation that suggests apoptosis has
been reported in skeletal muscle of septic rats,
whichwas prevented by administration of a TNF-a
antagonist, which suggests that TNF-a may
trigger apoptotic events in skeletal muscle during
inflammatory conditions [67]. This notion is fur-
ther supported by experiments in cultured myo-
blasts and myotubes, which revealed DNA
fragmentation after chronic exposure to TNF-a
[68], although differentiated myofibers seem to be
more resistant to TNF-a–induced apoptosis than
undifferentiated myoblasts [41]. Myoblasts ex-
posed to TNF-a show procaspase-8 cleavage [69],
whereas TNF-a–induced apoptosis in skeletalmus-
cle of patientswhohaveCOPDmaybemediated by
upregulation of inducible nitric oxide synthase in
myofibers [37]. Caspase-3 activation was reported
to contribute to myofibrillar protein degradation
in catabolic conditions [70] and was associated
withmuscleweakness in sepsis [71]. In chronic heart
failure, circulatory levels of TNF-a are increased,
which is paralleled by a rise in the number of apo-
ptotic nuclei in the soleus and tibialis anterior mus-
cles [72]. Despite these recent studies suggesting
a role of TNF-a and other inducers and mediators
of apoptotic signaling in skeletal muscle atrophy,
the relevance of these pathways in myofibers re-
mains to be established because of theirmultinucle-
ated nature and potential cell death–unrelated
consequences.
Myonuclear accretion and muscle regeneration
During conditions such as muscle growth,
recovery from atrophy, and muscle regeneration
after damage, myonuclear accretion is increased,
which requires activation of local muscle pre-
cursor cells, called satellite cells [65,73]. Upon ac-
tivation, these cells proliferate to form a pool of
myoblasts, which differentiate to fuse with exist-
ing myofibers or form new myofibers, processes
that are essential for efficient muscle growth, re-
growth, and regeneration [74]. Several groups
have demonstrated that TNF-a [40,75] and the re-
lated ligand TWEAK [76] as well as IL-1b inhibitmuscle differentiation and myoblast fusion
[75,77]. Inhibition of myogenesis by TNF-a re-
quires activation of NF-kB and involves repres-
sion of MyoD synthesis and protein stability
[78]. MyoD is a master regulator of myogenesis,
which explains the inability of myoblasts to ex-
press muscle-specific gene transcripts or form mul-
tinucleated myotubes in the presence of these
proinflammatory cytokines. Recent evidence also
showed that TNF-a could inhibit myogenesis
through the activation of caspases [79]. In a model
of chronic pulmonary (and systemic) inflamma-
tion, impaired muscle differentiation and regener-
ation was observed during muscle regrowth after
atrophy [35]. These data indicated that inflamma-
tory signaling may impair muscle differentiation
and myonuclear accretion, thereby compromising
the ability of the muscle to recover after injury or
atrophy and contributing to the loss of muscle
mass observed in several inflammatory conditions.
To conclude, the effects of inflammation on the
regulation of muscle mass may favor muscle
atrophy as a result of imbalances in protein
turnover and myonuclear turnover and likely
involve enhanced myofibrillar protein degradation
and/or reduced protein synthesis and activation of
apoptotic mechanisms and/or impaired myonu-
clear accretion. These processes are summarized
in Fig. 1.
Novel insights in the regulation of fiber type
and muscle oxidative phenotype
One of the most prominent features of skeletal
muscle is its high level of plasticity. Physical
activity level, nutritional status, and the presence
and/or absence of disease are important factors
determining muscle mass, fiber type composition,
and oxidative capacity. The muscle senses these
factors as mechanical, metabolic, neuronal, or
hormonal stimuli that lead to intracellular signal-
ing cascades that switch on or off specific gene
expression profiles (Fig. 2). In the following sec-
tion, some of the major key regulators of muscle
fiber type and oxidative phenotype are discussed.
A shift in muscle fiber type from type I (slow
twitch, oxidative, fatigue resistant) to type II
(fast twitch, glycolytic, fatigue prone) fibers has
been noted in muscle of patients who have
COPD [20].
Peroxisome proliferator-activated receptors
In the past decade, peroxisome proliferator-
activated receptors (PPARs) have emerged as
543SYSTEMIC INFLAMMATION AND SKELETAL MUSCLE DYSFUNCTION IN COPDFig. 1. Schematic overviewof the effects of inflammationon regulation of skeletalmusclemass by protein- andmyonuclear
turnover. Growth factors and cytokines that exert receptor-mediated effects (inverted triangles) are shown as diamonds, in-
tracellular mediators/signaling proteins are displayed as ovals, and intracellular processes are in plain text. Arrows indicate
activation, whereas blunted arrows indicate inhibition. IGF-1, insulin growth factor 1; IL-1, interleukin 1;MuRF1, muscle
ring finger-1; NF-kB, nuclear factor kappa B; TNF, tumor necrosis factor; UPP, ubiquitin proteasome pathway.positive regulators of skeletal muscle oxidative
phenotype [80,81]. There are three PPAR iso-
types: PPAR-a, PPAR-d, and PPAR-g, with the
latter having a low expression in skeletal muscle
and being implicated in storage of fatty acids.
On the other hand, the PPAR-a and PPAR-d iso-
types are highly expressed in skeletal muscle and
play a role in the transcriptional control of genes
that encode mitochondrial fatty acid b-oxidation
enzymes [80,81]. Many muscle genes that promote
selective use of lipid substrates are upregulated by
in vivo administration of PPAR-a activators. It
has been shown that skeletal muscle PPAR-a pro-
tein content is increased by exercise training and is
induced during myocyte differentiation, coinci-
dent with an increased oxidative capacity [82,83].
PPAR-a also regulates fatty acid use and expres-
sion of several genes involved in fatty acid b-oxi-
dation [84]. Based on these results, one would
expect that PPAR-a deficiency results in low rates
of b-oxidation in skeletal muscle [85].
Inconsistent with this hypothesis, however,
skeletal muscles from PPAR-a knock-out mice
exhibited only minor changes in fatty acid ho-
meostasis, and neither constitutive nor inducibleexpression of known PPAR-a target genes was
negatively affected by its absence. Skeletal muscle
also expresses high levels of PPAR-d. Activation
of the PPAR-d subtype increases fatty acid
b-oxidation and mRNA levels of several classical
PPAR-a target genes in rodent and human
skeletal muscle cells, and PPAR-d protein, like
PPAR-a protein, is induced in skeletal muscle
after exercise [86]. These results indicate that in
addition to PPAR-a, PPAR-d also plays an im-
portant role in mediating lipid-induced regulation
of oxidative pathways in skeletal muscle. Because
PPAR-d is the predominant subtype in skeletal
muscle and because isolated rat muscle is more
sensitive to a PPAR-d– than a PPAR-a–specific
agonist, a more prominent role for PPAR-d in
regulating skeletal muscle oxidative capacity has
been suggested [87]. Targeted overexpression of
PPAR-d or a constitutively active form of
PPAR-d in mouse skeletal muscle results in
a greater number of type I oxidative fibers in var-
ious muscles. This remodeling was caused by
hyperplasia or conversion of fibers to a more oxi-
dative phenotype, similar to what is observed in
endurance training [88].
544 REMELS et alFig. 2. Schematic overview of muscle oxidative phenotype regulation. Depending on the nature of the stimuli, specific
transcriptional pathways are switched on. Arrows indicate activation, whereas blunted arrows indicate inhibition.
Dashed arrows indicate less established relationships. FA, fatty acids; CnA, calcineurin; CaMK, calcium/calmodulin-
dependent kinases; AMPK, AMP-activated protein kinase; HIF-1a, hypoxia-inducible factor-1a; PPAR, peroxisome
proliferator-activated receptor; PGC-1, PPAR-g coactivator-1; mtTFA, mitochondrial transcriptional factor A.These histologic observations were confirmed
by the finding that muscle-specific PPAR-d over-
expression led to an increase of oxidative enzymes,
such as citrate synthase and b-hydroxyacylCoA
dehydrogenase. Conversely, activities of glycolytic
enzymes remained unchanged [88]. These observa-
tions were accompanied by the finding that trans-
genic mice with a constitutively activated form of
PPAR-d in skeletal muscle were capable of running
nearly twice as long as their wild-type littermates
without any physical training, which gave func-
tional meaning to these observations. Together,
these data strongly support a key role of PPAR-a
and PPAR-d in the regulation of fatty acid oxida-
tion in skeletal muscle and in the adaptive response
of this tissue to lipid catabolism [89].
Peroxisome proliferator-activated receptor-g
coactivator-1a
Probably the master regulator of oxidative
phenotype is the peroxisome proliferator-acti-
vated receptor-g coactivator-1 (PGC-1a). Its
name is misleading in two ways: it is not just
some coactivator secondary to the PPARs, and itis not only a coactivator of PPAR-g. PGC-1a is
described most in the context of mitochondrial
biogenesis, but it is likely that PGC1-b is also
somehow involved in the regulation of mitochon-
drial function [90]. PGC-1 overexpressing muscle
cells showed increased mitochondrial respiration,
upregulation of genes involved in oxidative phos-
phorylation, and increased mitochondrial DNA
content, all of which indicated enhanced mito-
chondrial biogenesis [91]. Two key transcription
factors in the regulation of mitochondrial func-
tiondthe nuclear respiratory factor-1 and the
mitochondrial transcription factor Adwere tran-
scriptionally upregulated by PGC-1. Nuclear re-
spiratory factor-1 coordinates the transcription
of genes involved in the electron transport chain
and that of mitochondrial transcription factor A,
which migrates to the mitochondria and initiates
transcription of mitochondrial-encoded genes [92].
In transgenic mice that overexpress PGC-1a in
the skeletal muscles, a clear fiber type II / I
(fast-to-slow) shift was observed, associated
with increased mitochondrial gene expression
[93].
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An illustrative study for a role of calcineurin in
muscle phenotype is that of Talmadge and col-
leagues [94], which showed that in transgenic mice
with muscle-specific overexpression of an active
form of calcineurin, the result was a fast-to-slow
fiber type shift. Similar results were observed in
cultured skeletal myotubes, in which transcription
of the slow fiber-specific genes troponin I slow and
myoglobin was stimulated by overexpression of
active calcineurin. Conversely, administration of
cyclosporin A, a calcineurin antagonist, induced
a slow-to-fast fiber type shift in rat muscles [95].
Calcium (Ca2þ) plays an important role in the ex-
citation-relaxation of muscle fibers upon neural
activation but also in the regulation of gene ex-
pression. The calcineurin-calmodulin complex is
activated by binding to Ca2þ and activates the
nuclear factor of activated T cells, which then
translocates to the nucleus and switches on slow
fiber-specific promoters. It is possible that this is
mediated through PGC-1a [96]. This process pref-
erentially occurs with low frequency or tonic mo-
tor nerve activity (typical for slow fibers), which is
associated with a sarcolemmal Ca2þ-influx
([Ca2þ]i) of low concentration but of sufficient
duration. In contrast, the calcineurin-nuclear fac-
tor of activated T cells pathway is insensitive to
shorter high-amplitude [Ca2þ]i evoked by high
frequency motor nerve activity (typical for fast
fibers). It is postulated that calcineurin plays an
important role in the translation of motor nerve
activity patterns into the expression profiles of
muscle fiber type–specific genes [95].
Calcium/calmodulin-dependent kinases
Other pathways by which Ca2þ influences mus-
cle oxidative phenotype are that of the calcium/
calmodulin-dependent kinases (CaMKs): CaMKII
and CaMKIV [97]. CaMKIV, when bound to
calmodulin-Ca2þ, is phosphorylated by CaMK ki-
nase and becomes transcriptionally active. Trans-
genic mice that overexpress CaMKIV in skeletal
muscles showed increased proportions of slow fi-
bers and enhanced mitochondrial biogenesis [98].
In these mice, the increase in mitochondrial con-
tent was associated with PGC-1, which suggested
that CaMKIV regulates oxidative phenotype
through PGC-1. Cultured myocytes that overex-
press CaMKIV showed enhanced PGC-1 reporter
gene expression [96]. CaMKII also has been sug-
gested to be involved in the regulation of mito-
chondrial biogenesis [97]. It consists of 12subunits that become sequentially autophosphory-
lated the longer CaMKII is bound to calmodulin-
Ca2þ, subsequently associated with an increasing
transcriptional activity of CaMKII. Like calci-
neurin, CaMKII seems to be able to decode stim-
ulation frequencies [97].
AMP-activated protein kinase
AMP-activated protein kinase (AMPK) plays
a critical role in regulating energy metabolism in
situations of critical energy demands (eg, as
a consequence of exercise) [99,100]. Contraction-
induced AMPK activity is highest in red muscles,
which are largely composed of slow (type I) fibers,
compared to white muscle, which contains mostly
fast (type II) fibers [101]. Acutely, low-energy sta-
tus (ie, increased AMP/ATP ratio) activates
AMPK, which in turn inhibits ATP-consuming
processes and activates substrate metabolism to
restore ATP levels. AMPK is also involved in
chronic adaptations through regulation of gene
expression. However, a broad range of genes in-
volved in energy metabolism have been shown
to be controlled by AMPK, most of which are in-
volved in oxidative metabolism, such as compo-
nents of the Krebs cycle and fatty acid oxidation
[99]. It has been demonstrated that chronic energy
deprivation enhances AMPK-dependent mito-
chondrial biogenesis associated with increased
protein levels of CaMKIV and PGC-1a [102],
which play an important role in muscle oxidative
phenotype.
Hypoxia-inducible factor-1a
Hypoxia-inducible factor-1a (HIF-1a) medi-
ates numerous adaptations of tissue to hypoxia.
Intramuscular partial pressure of oxygen drops
during exercise, and increased HIF-1a protein
levels have been reported in muscle from healthy
humans after exercise [103]. Likewise, it is possible
that this also occurs as a consequence of reduced
oxygen supply in diseases such as COPD and
chronic heart failure. During normoxia, HIF-1a
is hydroxylated at two proline residues by
prolyl-hydroxylases, which promote binding of
von Hippel-Lindau protein and target HIF-1a to
degradation by the ubiquitin-proteasome path-
way. When oxygen is limited, the prolyl-hydroxy-
lases are inhibited, and HIF-1a becomes
stabilized, migrates to the nucleus, dimerizes
with HIF-1b, and induces transcription of its tar-
get genes [104]. With respect to metabolic profiles,
these target genes are mainly genes involved in
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garded as a negative mediator of oxidative capac-
ity [105]. Exposure to hypoxia often induces
a shift toward glycolytic metabolism away from
oxidative metabolism [106]. Whether HIF-1a di-
rectly downregulates enzymes involved in oxida-
tive metabolism is less obvious, although data
from muscle-specific HIF-1a knock-out mice do
support this notion. Recent data also show that
the expression of PPARs is inhibited by HIF-1a
[107]. HIF-1a directly controls muscle oxidative
phenotype through regulation of the glycolytic
genes and possibly indirectly influences oxidative
phenotype via PPAR-dependent pathways.
It is plausible that all of these regulators are to
some degree involved in the loss of muscle
oxidative phenotype in COPD. Systemic inflam-
mation, a hallmark of COPD, may affect muscle
oxidative phenotype by downregulation of the
PPARs. It has been shown that a bidirectional
antagonism between the PPAR and NF-kB sig-
naling pathway exists. Several studies indepen-
dently reported that TNF-a and other
proinflammatory cytokines under transcriptional
control of NF-kB (eg, IL-6)din vitro and in
vivodexert a downregulating effect on the ex-
pression of PPAR mRNAs and have an inhibitory
effect on the transcriptional activity of PPAR
proteins [108–110]. Remels and colleagues [111]
recently demonstrated reduced PPAR levels that
correlated negatively with TNF-a levels in the cir-
culation in skeletal muscle of patients who have
COPD. The reduced daily physical activity pat-
terns of these patients imply reduced muscular
activity, especially endurance related, which could
attenuate the expression of oxidative genes
through the Ca2þ-dependent calcineurin and
CaMK pathways or via downregulation of the
PPARs [86]. In patients who have COPD, partic-
ularly persons who suffer from severe hypoxemia,
local hypoxia could cause a shift away from oxi-
dative metabolism through stabilization of HIF-
1a. Further investigation is needed to understand
more fully the spectrum of processes that regulate
fiber type shift and loss of muscle oxidative capac-
ity in skeletal muscle of patients who have COPD.
Therapeutic implications
Modulation of muscle atrophy
Several studies have investigated the effects of
exercise training and pharmacologic anabolic stim-
uli to promote protein synthesis in patients whohave COPD. Resistance exercise [112] and a com-
bined strength and endurance exercise approach
[113] resulted in gain of muscle mass. Anabolic ste-
roids, testosterone, growth hormone, and growth
hormone–releasing factor also showed a variable
but overall positive response on muscle mass
[114–116]. These studies illustrated that stimulation
of protein synthesis is a feasible therapeutic strat-
egy. No data are available yet regarding the
effects of these interventions on muscle IGF-1,
mechano growth factor-1 levels, and downstream
markers of IGF-1 signaling in COPD. The thera-
peutic potential of IGF-1 has been reflected mainly
by experimental studies in cultured cells and ani-
mals, in which stimulation of muscle growth and
prevention of aging- or disease-associated muscle
loss have beenwell documented. Recent insights re-
veal that two distinct cellular processes are involved
in postnatal muscle (re)growth: myofiber hypertro-
phy and muscle regeneration. As a result, the effect
of IGF-1 depends on which of these processes par-
ticipates in the growth response, because IGF-1 sig-
naling differs between muscle cells involved in
myofiber hypertrophy and muscle regeneration.
Basal IGF-1/insulin signaling is also required for
the maintenance of muscle mass by suppression of
muscle degradation pathways. It is essential to dis-
sect IGF-1 signal transduction in maintenance of
muscle mass and muscle growth responses involv-
ingmyofiber hypertrophy and regeneration (during
the stable clinical state and recovery from acute
exacerbations) to identify regulatory molecules as
putative candidates for specific pharmacologic
modulation of muscle growth and atrophy.
Another yet relatively unexplored possibility for
inducing or enhancing muscle weight gain is by
nutritional modulation of protein synthesis. Opti-
mizing protein intake may stimulate protein syn-
thesis per se but also may enhance efficacy of
anabolic drugs and physiologic stimuli, such as
resistance exercise. It has been shown in under-
weight patients who have COPD that exercise
training without nutritional rehabilitation is in-
sufficient to increase weight loss and muscle mass
[117]. Amino acids are the building blocks of pro-
tein, and several studies have to date reported an
abnormal plasma amino acid pattern in COPD.
Of interest are the consistently reduced plasma
levels of branched chain amino acids in under-
weight patients who have COPD and in patients
with low muscle mass [9]. In particular, leucine is
an interesting nutritional substrate because it not
only serves as precursor but also activates signaling
pathways that enhance activity and synthesis of
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gulate protein synthesis in skeletal muscle [118].
The anabolic response after tailored rehabili-
tation and pharmacologic stimulation is, however,
soon reversed when the anabolic stimulus is
terminated. Some patients who have COPD do
not respond at all [119]. Muscle wasting in COPD
may be the result of a perpetuating systemic
inflammatory response, because studies in experi-
mental models have demonstrated cachexia-
inducing effects of proinflammatory cytokines,
such as TNF-a, IL-1, and IL-6. Cross-sectional
studies provide evidence for inflammation as
a trigger of muscle atrophy, and systemic inflam-
mation seemed to discriminate patients with
a poor therapeutic response to a standardized
and controlled clinical rehabilitation program
from so-called ‘‘responders’’ [120]. Because in-
creased levels of multiple inflammatory mediators
have been reported in COPD, further work is
needed to determine which of these mediators
should be targeted to prevent muscle atrophy in
patients who have COPD.
From a therapeutic perspective, it would the-
oretically be more effective to modulate muscle
metabolism at a level at which many of these
stimuli converge (ie, activation of NF-kB in
skeletal muscle itself). Evidence to support such
a strategy is provided by several recent studies
that revealed that NF-kB activation in skeletal
muscle is required for the induction of muscle loss
by several atrophy stimuli [55,56,121], and induc-
tion of NF-kB specifically in skeletal muscle is
sufficient to induce atrophy [55]. Importantly, in-
activation of muscular NF-kB was also docu-
mented to stimulate muscle differentiation
[55,75,122], promote muscle regeneration, and in-
crease muscle strength [121]. Alternatively, strate-
gies to increase local IGF-1 also may exert
inflammatory signaling-suppressive effects [123].
This strategy would positively modulate muscle
mass by overcoming the suppressive effects of in-
flammation on muscle regeneration and stimula-
tion of muscle growth via IGF-1 signaling.
Regulation of muscle metabolism
Positive effects of pulmonary rehabilitation
(particularly endurance exercise training) on oxi-
dative enzymes and exercise capacity illustrate
that decreased muscle oxidative capacity in
COPD is at least partly reversible [124]. Exercise
training also seemed to restore UCP-3 content in
limb muscles, especially in patients who showedno increase in hydroxyacylCoA dehydrogenase
activity, whereas lipid peroxidation levels were un-
altered [125]. The nature of this response complies
with the hypothesis that UCP-3 may protect
against lipotoxicity (possibly induced or aggra-
vated by oxidative stress) and that antioxidant
modulation or fatty acid modulation may posi-
tively affect these processes. This may be useful
in pulmonary and systemic circumstances that
limit high-intensity exercise, such as severe respi-
ratory impairment or cachexia.
A recent report provided evidence for electron
transport chain dysfunction of mitochondria in
cachectic patients who have COPD and were
otherwise characterized by low UCP-3 mRNA
expression and abnormal adaptations of skeletal
muscle redox status after exercise training
[22,126]. A recent randomized clinical trial of
patients who have COPD participating in a pul-
monary rehabilitation program showed that poly-
unsaturated fatty acids markedly enhanced
exercise capacity compared to placebo [127].
These positive effects also could be explained by
modulating effects on PPAR content and activity
in skeletal muscle, because polyunsaturated fatty
acids are natural ligands of the PPARs. Impor-
tantly, there is experimental evidence that PPARs
also can exert anti-inflammatory effects in airways
and muscle cells, thereby not limiting their prom-
ising beneficial effects on the pathogenesis
of COPD to the extrapulmonary manifestations
of the disease but expanding them to the level of
the primary organ dysfunction [128,129].
Summary
Efficacy of known interventions to modulate
skeletal muscle function, together with novel
insights in the regulation of muscle mass and
muscle metabolism as summarized in this article,
provides increasing evidence of the need for
therapeutic strategies to improve skeletal muscle
oxidative capacity and muscle protein synthesis
and regulate systemic inflammation and oxidative
stress, which are strongly associated with skeletal
muscle atrophy and dysfunction in COPD and
other chronic disorders.
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